Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Glucopyranosyl lipid adjuvant enhances immune response to Ebola virus-like particle vaccine in mice.

Sunay MME, Martins KAO, Steffens JT, Gregory M, Vantongeren SA, Van Hoeven N, Garnes PG, Bavari S.

Vaccine. 2019 Jun 27;37(29):3902-3910. doi: 10.1016/j.vaccine.2019.05.026. Epub 2019 Jun 4.

PMID:
31174937
2.

Memory CD4+ T cells enhance B-cell responses to drifting influenza immunization.

Gage E, Van Hoeven N, Dubois Cauwelaert N, Larsen SE, Erasmus J, Orr MT, Coler RN.

Eur J Immunol. 2019 Feb;49(2):266-276. doi: 10.1002/eji.201847852. Epub 2018 Dec 21.

PMID:
30548475
3.

Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani.

Duthie MS, Van Hoeven N, MacMillen Z, Picone A, Mohamath R, Erasmus J, Hsu FC, Stinchcomb DT, Reed SG.

Front Immunol. 2018 Oct 17;9:2420. doi: 10.3389/fimmu.2018.02420. eCollection 2018.

4.

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.

Van Hoeven N, Wiley S, Gage E, Fiore-Gartland A, Granger B, Gray S, Fox C, Clements DE, Parks DE, Winram S, Stinchcomb DT, Reed SG, Coler RN.

NPJ Vaccines. 2018 Sep 26;3:39. doi: 10.1038/s41541-018-0077-1. eCollection 2018.

5.

The adjuvant GLA-AF enhances human intradermal vaccine responses.

Carter D, van Hoeven N, Baldwin S, Levin Y, Kochba E, Magill A, Charland N, Landry N, Nu K, Frevol A, Ashman J, Sagawa ZK, Beckmann AM, Reed SG.

Sci Adv. 2018 Sep 12;4(9):eaas9930. doi: 10.1126/sciadv.aas9930. eCollection 2018 Sep.

6.

A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Erasmus JH, Khandhar AP, Guderian J, Granger B, Archer J, Archer M, Gage E, Fuerte-Stone J, Larson E, Lin S, Kramer R, Coler RN, Fox CB, Stinchcomb DT, Reed SG, Van Hoeven N.

Mol Ther. 2018 Oct 3;26(10):2507-2522. doi: 10.1016/j.ymthe.2018.07.010. Epub 2018 Aug 2.

PMID:
30078765
7.

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.

Baldwin SL, Hsu FC, Van Hoeven N, Gage E, Granger B, Guderian JA, Larsen SE, Lorenzo EC, Haynes L, Reed SG, Coler RN.

Front Immunol. 2018 Feb 19;9:295. doi: 10.3389/fimmu.2018.00295. eCollection 2018.

8.

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Van Hoeven N, Fox CB, Granger B, Evers T, Joshi SW, Nana GI, Evans SC, Lin S, Liang H, Liang L, Nakajima R, Felgner PL, Bowen RA, Marlenee N, Hartwig A, Baldwin SL, Coler RN, Tomai M, Elvecrog J, Reed SG, Carter D.

Sci Rep. 2017 Apr 21;7:46426. doi: 10.1038/srep46426.

9.

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG.

J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. Epub 2016 Nov 12.

10.

Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites.

Hofmeyer KA, Duthie MS, Laurance JD, Favila MA, Van Hoeven N, Coler RN, Reed SG.

Clin Vaccine Immunol. 2016 Sep 6;23(9):785-94. doi: 10.1128/CVI.00251-16. Print 2016 Sep.

11.

Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice.

Gray SA, Moore M, VandenEkart EJ, Roque RP, Bowen RA, Van Hoeven N, Wiley SR, Clegg CH.

Antiviral Res. 2016 Jul;131:100-8. doi: 10.1016/j.antiviral.2016.04.001. Epub 2016 Apr 21.

12.

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.

Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, Reed SG, Coler RN.

PLoS One. 2016 Feb 22;11(2):e0149610. doi: 10.1371/journal.pone.0149610. eCollection 2016.

13.

Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.

Stavaru C, Onu A, Lupulescu E, Tucureanu C, Rasid O, Vlase E, Coman C, Caras I, Ghiorghisor A, Berbecila L, Tofan V, Bowen RA, Marlenee N, Hartwig A, Bielefeldt-Ohmann H, Baldwin SL, Van Hoeven N, Vedvick TS, Huynh C, O'Hara MK, Noah DL, Fox CB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30.

14.

Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.

Tareen SU, Kelley-Clarke B, Nicolai CJ, Cassiano LA, Nelson LT, Slough MM, Vin CD, Odegard JM, Sloan DD, Van Hoeven N, Allen JM, Dubensky TW Jr, Robbins SH.

Mol Ther. 2014 Mar;22(3):575-587. doi: 10.1038/mt.2013.278. Epub 2013 Dec 6.

15.

Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses.

Desbien AL, Van Hoeven N, Reed SJ, Casey AC, Laurance JD, Baldwin SL, Duthie MS, Reed SG, Carter D.

Biotechniques. 2013 Jun;54(6):345-8. doi: 10.2144/000114041.

16.

Adjuvant solution for pandemic influenza vaccine production.

Clegg CH, Roque R, Van Hoeven N, Perrone L, Baldwin SL, Rininger JA, Bowen RA, Reed SG.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17585-90. doi: 10.1073/pnas.1207308109. Epub 2012 Oct 8.

17.

Local innate immune responses and influenza virus transmission and virulence in ferrets.

Maines TR, Belser JA, Gustin KM, van Hoeven N, Zeng H, Svitek N, von Messling V, Katz JM, Tumpey TM.

J Infect Dis. 2012 Feb 1;205(3):474-85. doi: 10.1093/infdis/jir768. Epub 2011 Dec 9.

PMID:
22158704
18.

Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets.

Gustin KM, Maines TR, Belser JA, van Hoeven N, Lu X, Dong L, Isakova-Sivak I, Chen LM, Voeten JT, Heldens JG, van den Bosch H, Cox NJ, Tumpey TM, Klimov AI, Rudenko L, Donis RO, Katz JM.

J Infect Dis. 2011 Nov 15;204(10):1491-9. doi: 10.1093/infdis/jir596. Epub 2011 Sep 28.

PMID:
21957153
19.

Effect of receptor binding domain mutations on receptor binding and transmissibility of avian influenza H5N1 viruses.

Maines TR, Chen LM, Van Hoeven N, Tumpey TM, Blixt O, Belser JA, Gustin KM, Pearce MB, Pappas C, Stevens J, Cox NJ, Paulson JC, Raman R, Sasisekharan R, Katz JM, Donis RO.

Virology. 2011 Apr 25;413(1):139-47. doi: 10.1016/j.virol.2011.02.015. Epub 2011 Mar 23.

20.

Multiple genes contribute to the virulent phenotype observed in ferrets of an H5N1 influenza virus isolated from Thailand in 2004.

Maines TR, Chen LM, Belser JA, Van Hoeven N, Smith E, Donis RO, Tumpey TM, Katz JM.

Virology. 2011 May 10;413(2):226-30. doi: 10.1016/j.virol.2011.02.005. Epub 2011 Mar 8.

21.

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, Lu X, DeVos J, Hancock K, Katz JM, Vedvick TS, Duthie MS, Clegg CH, Van Hoeven N, Reed SG.

PLoS One. 2010 Oct 27;5(10):e13677. doi: 10.1371/journal.pone.0013677.

22.

Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret.

Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, Andersen H, Tumpey TM, Nabel GJ.

PLoS One. 2010 Mar 23;5(3):e9812. doi: 10.1371/journal.pone.0009812.

23.

Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment.

Jackson S, Van Hoeven N, Chen LM, Maines TR, Cox NJ, Katz JM, Donis RO.

J Virol. 2009 Aug;83(16):8131-40. doi: 10.1128/JVI.00534-09. Epub 2009 Jun 3.

24.

The public health impact of avian influenza viruses.

Katz JM, Veguilla V, Belser JA, Maines TR, Van Hoeven N, Pappas C, Hancock K, Tumpey TM.

Poult Sci. 2009 Apr;88(4):872-9. doi: 10.3382/ps.2008-00465.

PMID:
19276438
25.

Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air.

Van Hoeven N, Pappas C, Belser JA, Maines TR, Zeng H, García-Sastre A, Sasisekharan R, Katz JM, Tumpey TM.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3366-71. doi: 10.1073/pnas.0813172106. Epub 2009 Feb 11.

26.

Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding.

Van Hoeven N, Belser JA, Szretter KJ, Zeng H, Staeheli P, Swayne DE, Katz JM, Tumpey TM.

J Virol. 2009 Apr;83(7):2851-61. doi: 10.1128/JVI.02174-08. Epub 2009 Jan 14.

27.

Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility.

Belser JA, Blixt O, Chen LM, Pappas C, Maines TR, Van Hoeven N, Donis R, Busch J, McBride R, Paulson JC, Katz JM, Tumpey TM.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7558-63. doi: 10.1073/pnas.0801259105. Epub 2008 May 27.

28.

Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus.

Baskin CR, Bielefeldt-Ohmann H, García-Sastre A, Tumpey TM, Van Hoeven N, Carter VS, Thomas MJ, Proll S, Solórzano A, Billharz R, Fornek JL, Thomas S, Chen CH, Clark EA, Murali-Krishna K, Katze MG.

J Virol. 2007 Nov;81(21):11817-27. Epub 2007 Aug 22. Erratum in: J Virol. 2007 Dec;81(24):13943.

29.

The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses.

Tumpey TM, Szretter KJ, Van Hoeven N, Katz JM, Kochs G, Haller O, García-Sastre A, Staeheli P.

J Virol. 2007 Oct;81(19):10818-21. Epub 2007 Jul 25.

30.

Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.

Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA.

Vaccine. 2007 May 22;25(21):4283-90. Epub 2007 Mar 9.

PMID:
17403562
31.

A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission.

Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solórzano A, Pappas C, Cox NJ, Swayne DE, Palese P, Katz JM, García-Sastre A.

Science. 2007 Feb 2;315(5812):655-9.

32.

Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics.

Baas T, Baskin CR, Diamond DL, García-Sastre A, Bielefeldt-Ohmann H, Tumpey TM, Thomas MJ, Carter VS, Teal TH, Van Hoeven N, Proll S, Jacobs JM, Caldwell ZR, Gritsenko MA, Hukkanen RR, Camp DG 2nd, Smith RD, Katze MG.

J Virol. 2006 Nov;80(21):10813-28. Epub 2006 Aug 23.

36.

Evidence that ORF3 at the Streptococcus parasanguis fimA locus encodes a thiol-specific antioxidant.

Spatafora G, Van Hoeven N, Wagner K, Fives-Taylor P.

Microbiology. 2002 Mar;148(Pt 3):755-62.

PMID:
11882710
37.

Supplemental Content

Loading ...
Support Center